Latest Daily News

Latest News
June 6, 2017

In contrast to more common cancers, some sarcoma subsets are fairly rare and standard treatments have not been established. However, for each sarcoma type discussed, strategies are being developed with the aim of improving outcomes for patients with sarcoma.

Read more
June 4, 2017

Although new discoveries regarding the biology of sarcoma are occurring at a historic pace, novel drug development in this rare cancer is complicated by the heterogeneous nature of disease.

Read more

June 3, 2017

Pembrolizumab is a potentially viable treatment for a subset of sarcomas, with promising activity in undifferentiated pleomorphic sarcoma and liposarcoma.

Read more
June 3, 2017

Aldoxorubicin prolonged progression-free survival in patients with liposarcoma and leiomyosarcoma (L-sarcoma) compared with standard treatments in a phase III study.

Read more
June 6, 2016

Drug development in oncology is providing much-needed new therapies to patients living with cancer. 

Read more

June 7, 2016

High-dose busulfan-melphalan followed by autologous stem cell rescue may be an effective treatment for highly selected patients with localized high-risk Ewing sarcoma but does not provide a significant efficacy benefit in patients with lung metastases, suggest results from two randomized trials.

Read more
May 31, 2015

The Center for Cancer and Blood Disorders is participating in the COME HOME project, an innovative medical home model with the goal of improving health outcomes, enhancing patient care experiences, and significantly reduce costs of care.

Read more
June 1, 2015

In a randomized, open-label phase III trial, trabectedin failed to show OS improvement over dacarbazine in patients with advanced liposarcoma or leiomyosarcoma but it did show a significant improvement in progression-free survival.

Read more
May 31, 2015

The PET-NECK trial was conducted to evaluate the efficacy and cost-effectiveness of PET-CT guided surveillance compared with planned neck dissection in patients with head and neck squamous cell carcinoma.

Read more
June 7, 2015

The CD38-targeted monoclonal antibody daratumumab shows promising single-agent activity in patients with heavily pretreated relapsed and refractory multiple myeloma. 

Read more
June 1, 2015

In his overview of GeDDiS, discussant Dr. Laurence H. Baker called upon the sarcoma research community to agree on standard criteria for trials of this nature to accelerate the delivery of better therapies for patients with STS.

Read more